Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00367016 · ClinicalTrials.gov registry record · Phase 4
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
A Phase 4 study of Asthma and Atopic Dermatitis, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT00367016: Completed Phase 4 study of Asthma and Atopic Dermatitis, sponsored by University of California, Davis.
NCT00367016 is a Phase 4 study of Asthma and Atopic Dermatitis that has completed, run by University of California, Davis. The registered enrollment target is 6 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00367016, a Phase 4 study of Asthma and Atopic Dermatitis, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to look at measures that will help scientists understand the way Omalizumab, an FDA-approved anti-allergy medication, works.
Primary Outcome
Skin biopsies were collected from patients after 0 (pre), 3 (pos1) and 6 (pos2) months of omalizumab (P11, P36, P42) or placebo (P7 and P38) treatment. The skin was fixed and the paraffin-embedded sections were stained for high affinity receptors. The average numbers of positively stained cells in each field were counted under a microscope at 400X magnification.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Omalizumab
Study Locations (1)
California
- UC Davis Department of Dermatology - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2004-02 |
| Est. Completion | 2012-10-17 |
| Phase | Phase 4 |
What the finished NCT00367016 record still lists
NCT00367016 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00367016 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00367016 about?
NCT00367016 is a clinical study titled "Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)". The purpose of this study is to look at measures that will help scientists understand the way Omalizumab, an FDA-approved anti-allergy medication, works.
What is the current status of trial NCT00367016?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2004-02. Estimated completion is 2012-10-17.
What conditions does trial NCT00367016 study?
This clinical trial studies the following conditions: Asthma, Atopic Dermatitis, Allergic Rhinitis.
What interventions are being tested in trial NCT00367016?
The interventions under investigation include: Placebo (DRUG), Omalizumab (DRUG).
Who is sponsoring clinical trial NCT00367016?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00367016 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00367016's enrollment target sits among peer trials
6 372nd of 374 higher than 1 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia